CO6361953A2 - Fusiones y conjugados de fármaco - Google Patents

Fusiones y conjugados de fármaco

Info

Publication number
CO6361953A2
CO6361953A2 CO11124244A CO11124244A CO6361953A2 CO 6361953 A2 CO6361953 A2 CO 6361953A2 CO 11124244 A CO11124244 A CO 11124244A CO 11124244 A CO11124244 A CO 11124244A CO 6361953 A2 CO6361953 A2 CO 6361953A2
Authority
CO
Colombia
Prior art keywords
fusions
drug
conjugates
relates
glp
Prior art date
Application number
CO11124244A
Other languages
English (en)
Inventor
Christopher Herring
Lucy J Holt
Malgorzada Pupeka
Sebastian Mayer
Laurent S Jespers
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42308293&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6361953(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CO6361953A2 publication Critical patent/CO6361953A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a fusiones de fármaco que tienen semividas en suero mejoradas. Estas fusiones y conjugados comprenden polipéptidos, dominios variables únicos de inmunoglobulina (anticuerpos) y moléculas de GLP y/o exendina. La invención se refiere además a usos, formulaciones, composiciones y dispositivos que comprenden tales fusiones y conjugados de fármaco.
CO11124244A 2009-03-27 2011-09-22 Fusiones y conjugados de fármaco CO6361953A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16391709P 2009-03-27 2009-03-27

Publications (1)

Publication Number Publication Date
CO6361953A2 true CO6361953A2 (es) 2012-01-20

Family

ID=42308293

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11124244A CO6361953A2 (es) 2009-03-27 2011-09-22 Fusiones y conjugados de fármaco

Country Status (24)

Country Link
US (2) US8779103B2 (es)
EP (1) EP2411054A2 (es)
JP (1) JP2012521971A (es)
KR (1) KR20110137819A (es)
CN (2) CN104127880A (es)
AR (1) AR076147A1 (es)
AU (1) AU2010227552B2 (es)
BR (1) BRPI1013588A2 (es)
CA (1) CA2756853A1 (es)
CL (1) CL2011002387A1 (es)
CO (1) CO6361953A2 (es)
DO (1) DOP2011000288A (es)
EA (1) EA021146B1 (es)
IL (1) IL215200A0 (es)
MA (1) MA33221B1 (es)
MX (1) MX2011010151A (es)
NZ (1) NZ595344A (es)
PE (1) PE20120514A1 (es)
SG (1) SG174497A1 (es)
TW (1) TW201100104A (es)
UA (1) UA98911C2 (es)
UY (1) UY32514A (es)
WO (1) WO2010108937A2 (es)
ZA (1) ZA201107022B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104127880A (zh) * 2009-03-27 2014-11-05 葛兰素集团有限公司 药用融合体和缀合物
US20120276098A1 (en) * 2009-09-30 2012-11-01 Bruce Hamilton Drug fusions and conjugates with extended half life
CN103003303A (zh) 2010-05-20 2013-03-27 葛兰素集团有限公司 改进的抗-血清白蛋白结合变体
MX336540B (es) 2010-06-08 2016-01-22 Genentech Inc Conjugados y anticuerpos manipulados geneticamente con cisteina.
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
WO2012136790A1 (en) * 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
AU2012271974B2 (en) * 2011-06-23 2017-01-12 Ablynx Nv Serum albumin binding proteins
BR122017005075B1 (pt) 2011-06-23 2022-09-20 Ablynx N.V Técnicas para prever, detectar e reduzir interferência de proteína não especifica em ensaios envolvendo domínios variáveis únicos de imunoglobulina
CN102949730A (zh) * 2011-09-16 2013-03-06 西藏海思科药业集团股份有限公司 特异结合glp-1受体的药物融合体
CN102949731A (zh) * 2011-09-16 2013-03-06 西藏海思科药业集团股份有限公司 与glp-2受体特异性结合的药物融合体
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
CN102875675B (zh) * 2012-04-26 2015-05-27 拜明(苏州)生物技术有限公司 抗人血清白蛋白单链抗体及其氮端连接多肽药物的方法
CN102827277B (zh) * 2012-04-26 2014-12-10 拜明(苏州)生物技术有限公司 抗人血清白蛋白单链抗体及其碳端连接多肽药物的方法
CA2897345A1 (en) * 2013-01-31 2014-08-07 Glaxo Group Limited Method of producing a protein
MA39301A1 (fr) 2014-01-20 2018-01-31 Hanmi Pharmaceutical Co Ltd Insuline à action prolongée et utilisation associée
RU2016137264A (ru) * 2014-02-21 2018-03-26 МЕДИММЬЮН, ЭлЭлСи Слияния антитела к pcsk9~glp-1 и способы применения
DK3248986T3 (da) 2014-05-16 2022-04-04 Ablynx Nv Variable immunoglobulindomæner
AR100639A1 (es) * 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
EP3191521A2 (en) 2014-09-12 2017-07-19 F. Hoffmann-La Roche AG Cysteine engineered antibodies and conjugates
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
CN115837014A (zh) * 2016-05-18 2023-03-24 摩登纳特斯有限公司 编码松弛素的多核苷酸
JP7158378B2 (ja) 2016-09-23 2022-10-21 ハンミ ファーマシューティカル カンパニー リミテッド インスリン受容体との結合力が減少された、インスリンアナログ及びその用途
CN107281471A (zh) * 2017-06-26 2017-10-24 中国药科大学 一种改构的胰高血糖素样肽－1及其修饰物的应用
US11752216B2 (en) 2017-03-23 2023-09-12 Hanmi Pharm. Co., Ltd. Insulin analog complex with reduced affinity for insulin receptor and use thereof
TWI809515B (zh) 2017-12-21 2023-07-21 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
TWI767095B (zh) 2017-12-21 2022-06-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
ES2929416T3 (es) 2018-06-21 2022-11-29 Novo Nordisk As Nuevos compuestos para el tratamiento de la obesidad
CN111234015B (zh) * 2020-02-12 2021-04-06 康维众和(中山)生物药业有限公司 用于延长药物半衰期的抗体、其融合蛋白和应用
WO2021182928A1 (ko) * 2020-03-12 2021-09-16 주식회사 에스엘메타젠 신규 이중 특이성 단백질 및 그의 용도
WO2022015039A1 (ko) * 2020-07-14 2022-01-20 (주)지아이이노베이션 글루카곤-유사 펩타이드-1 및 글루카곤-유사 펩타이드-2를 포함하는 융합 단백질 및 이의 용도

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
ATE193541T1 (de) 1989-03-20 2000-06-15 Gen Hospital Corp Insulinotropes hormon
DE69129226T2 (de) 1990-01-24 1998-07-30 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
DK36492D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
DK0966297T4 (da) 1996-08-08 2013-03-18 Amylin Pharmaceuticals Llc Regulering af gastrointestinal motilitet
ES2283936T3 (es) 1997-07-07 2007-11-01 Medical Research Council Procedimiento de clasificacion in vitro.
NZ502592A (en) 1997-08-08 2002-03-28 Amylin Pharmaceuticals Inc Exendin agonist peptides and their use in the treatment of type I and II diabetes
ES2297902T5 (es) 1997-11-14 2013-07-09 Amylin Pharmaceuticals, Inc. Compuestos novedosos agonistas de exendina
MXPA00004670A (es) 1997-11-14 2003-07-14 Amylin Pharmaceuticals Inc Compuestos agonistas de exendina novedosos.
AU759058C (en) 1998-02-13 2005-09-15 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
AU3247799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
SI1355942T1 (sl) 2000-12-07 2009-02-28 Lilly Co Eli Glp-1 fuzijski proteini
JP5562510B2 (ja) 2001-06-28 2014-07-30 ノヴォ ノルディスク アー／エス 修飾ｇｌｐ−１の安定な処方剤
EP1463752A4 (en) 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005027978A2 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
KR20120133403A (ko) * 2004-06-01 2012-12-10 도만티스 리미티드 증강된 혈청 반감기를 가지는 이특이성 융합 항체
US20060052301A1 (en) 2004-06-03 2006-03-09 Ronen Shemesh Splice variants of peptide YY, neuropeptide Y, pancreatic peptide Y and Amylin, and uses thereof
US20090214534A1 (en) * 2004-12-02 2009-08-27 Steve Holmes Bispecific Domain Antibodies Targeting Serum Albumin And GLP-1 Or PYY
GB0724331D0 (en) * 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
CA2718480A1 (en) * 2008-03-31 2009-10-08 Glaxo Group Limited Drug fusions and conjugates
EP2398825B1 (en) * 2009-02-19 2017-10-25 Glaxo Group Limited Single variable domain against serum albumin
CA3079184A1 (en) * 2009-02-19 2010-08-26 Glaxo Group Limited Improved anti-serum albumin binding variants
CN104127880A (zh) * 2009-03-27 2014-11-05 葛兰素集团有限公司 药用融合体和缀合物
US20120276098A1 (en) * 2009-09-30 2012-11-01 Bruce Hamilton Drug fusions and conjugates with extended half life

Also Published As

Publication number Publication date
AU2010227552A1 (en) 2011-11-03
PE20120514A1 (es) 2012-05-14
NZ595344A (en) 2013-09-27
ZA201107022B (en) 2013-03-27
US20140193407A1 (en) 2014-07-10
MX2011010151A (es) 2011-12-14
CA2756853A1 (en) 2010-09-30
EP2411054A2 (en) 2012-02-01
WO2010108937A2 (en) 2010-09-30
MA33221B1 (fr) 2012-04-02
EA021146B1 (ru) 2015-04-30
AU2010227552B2 (en) 2015-02-26
AR076147A1 (es) 2011-05-18
CL2011002387A1 (es) 2012-07-20
UY32514A (es) 2010-10-29
SG174497A1 (en) 2011-10-28
CN102481373A (zh) 2012-05-30
CN104127880A (zh) 2014-11-05
DOP2011000288A (es) 2012-01-15
BRPI1013588A2 (pt) 2016-04-19
US8779103B2 (en) 2014-07-15
WO2010108937A3 (en) 2010-11-25
EA201190184A1 (ru) 2012-05-30
IL215200A0 (en) 2011-12-29
US20120100141A1 (en) 2012-04-26
JP2012521971A (ja) 2012-09-20
KR20110137819A (ko) 2011-12-23
UA98911C2 (uk) 2012-06-25
TW201100104A (en) 2011-01-01

Similar Documents

Publication Publication Date Title
CO6361953A2 (es) Fusiones y conjugados de fármaco
MX2010010776A (es) Fusiones y conjugados de farmaco.
MX2012003939A (es) Fusiones y conjugados de farmaco.
CY1124500T1 (el) Συνθεση που περιλαμβανει αντισωμα που δεσμευεται με περιοχη ii toy her2 και οξινες παραλλαγες αυτου
BR112015008311A2 (pt) conjugados fármaco-proteína
CL2013001279A1 (es) Anticuerpo humano aislado o fragmento de union a antigeno del mismo que se une especificamente y neutraliza la actividad del ligando 1a de tipo tnf humano (htl1a); molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso.
EA201491441A1 (ru) Композиции конъюгата xten и способы их получения
WO2013184938A3 (en) Fusion polypeptides comprising mucin-domain polypeptide linkers
BR112015012933A2 (pt) proteínas de ligação ao antígeno bcma
BR112014019611A2 (pt) agentes de ligação mica
MX2019014833A (es) Conjugacion de anticuerpo-farmaco especifica de sitio mediante glicoingenieria.
MX2012000765A (es) Dominios variables sencillos de union de albumina anti-suero mejorados.
BR112012025568A2 (pt) proteínas de ligação ao tnf-<244>.
BR112012007523A2 (pt) moléculas de anticorpo anti-gcc e composições e métodos relacionados
BR112017022256A2 (pt) conjugados de anticorpo-droga sítio-específicos
WO2011086143A3 (en) Liver targeting domain antibodies
MA34025B1 (fr) Polypeptides se liant au bêta-a
BR112014023415A2 (pt) moléculas que se ligam a ang2
EA201590412A1 (ru) Композиции антител и их применения
IL237345B (en) Antibody and drug conjugates (adc) that bind to 158p1d7 proteins, preparations containing them and their uses
MX2011008752A (es) Variantes de union a anti-albumina de suero mejoradas.
BR112013013003A2 (pt) proteína de ligação de antígeno, e, composição farmacêutica
UY35854A (es) Métodos para la conjugación de oxima con polipéptidos ceto-modificados
BR112017022252A2 (pt) conjugados de anticorpo-droga sítio-específicos
MX2016008355A (es) Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos.

Legal Events

Date Code Title Description
FG Application granted